Cdc4 activators are a relatively rare class of compounds due to the complexity of enhancing the activity of a protein within the ubiquitin-proteasome pathway. Cdc4, also known as F-box protein, is an integral part of the SCF complex, which is pivotal in tagging specific proteins with ubiquitin for degradation. Cdc4's primary function involves the recognition and binding of certain phosphorylated sequences on substrates, which earmarks them for ubiquitination and subsequent proteolysis. Activators of Cdc4 could potentially enhance this recognition process or stabilize the interaction between Cdc4 and its substrate proteins, thereby increasing the efficiency of protein ubiquitination. The exact mechanism by which these activators could augment Cdc4 activity is not straightforward, as it could involve multiple biochemical pathways and protein interactions. Nevertheless, such compounds would need to interact with the Cdc4 protein or modulate its associated partners within the SCF complex without disrupting the normal regulatory mechanisms that prevent aberrant protein degradation.
The chemical structure of Cdc4 activators would likely be diverse, tailored to interact with the specific interfaces between Cdc4 and its substrate proteins or to modulate the assembly and function of the SCF complex. These activators might come in the form of small molecules that bind to allosteric sites on Cdc4, altering its conformation in a way that improves substrate recognition or affinity. Alternatively, they could interact with the regulatory components of the SCF complex, enhancing the E3 ligase activity and thus promoting a more robust ubiquitination process. The design of such molecules would require an intricate knowledge of the Cdc4 structure and the dynamics of its interaction with both the SCF complex and the target substrates. This entails not only the understanding of the binding sites and the key amino acid residues involved in the interactions but also the temporal aspect of the ubiquitination process.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, indirectly activates Cdc4. By inhibiting the proteasome, MG-132 stabilizes Cdc4, preventing its degradation. This leads to an increased pool of active Cdc4, enhancing its role in ubiquitin-dependent proteolysis and cell cycle regulation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924, a NEDD8-activating enzyme inhibitor, indirectly activates Cdc4 by disrupting cullin neddylation. Inhibition of neddylation prevents SCF complex activation, leading to the stabilization of Cdc4-bound substrates. This indirect modulation emphasizes the regulatory role of neddylation in Cdc4 function, providing insights into the dynamic control of ubiquitin-dependent proteolysis. | ||||||
SMER28 | 307538-42-7 | sc-222320 | 10 mg | $173.00 | ||
SMER28, an autophagy inducer, indirectly influences Cdc4 through autophagy modulation. By inducing autophagy, SMER28 promotes the degradation of specific substrates, indirectly impacting Cdc4 activity. This indirect activation highlights the crosstalk between autophagy and ubiquitin-dependent proteolysis, providing insights into the intricate regulatory mechanisms governing cellular protein turnover. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, a CDK inhibitor, directly influences Cdc4 by inhibiting CDKs. Through this inhibition, Flavopiridol disrupts the phosphorylation events that regulate Cdc4 activity. By modulating CDK-dependent pathways, Flavopiridol indirectly supports Cdc4 activation, illustrating the interconnected nature of CDKs and Cdc4 in the control of cell cycle progression. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3, a p53-MDM2 interaction inhibitor, indirectly activates Cdc4 by influencing the p53 pathway. Inhibition of p53-MDM2 interaction by Nutlin-3 prevents MDM2-mediated degradation of Cdc4, leading to its stabilization. This indirect modulation provides insights into the intricate crosstalk between the p53 pathway and Cdc4-mediated ubiquitin-dependent proteolysis. | ||||||